abcam

ab213038

# Anti-CD22 antibody [MYG13] - BSA and Azide free

## Key facts

| | |
|---|---|
| **Isotype** | IgG1 |
| **Host species** | Mouse |
| **Storage buffer** | pH: 7.2 - 7.4 Constituents: PBS |
| **Form** | Liquid |
| **Clonality** | Monoclonal |
| **Immunogen** | Cell preparation containing CD22 protein. The exact immunogen used to generate this antibody is proprietary information. Database link P20273 |
| **Carrier free** | Yes |
| **Clone number** | MYG13 |
| **Purification technique** | Affinity purification Protein A/G |
| **Light chain type** | kappa |
| **Concentration** | 1 mg/mL The concentration of this product may be batch-dependent<br>Batch concentration finder → |
| **Purification notes** | Purified from bioreactor concentrate by Protein A/G. |

## Reactivity data

## Flow Cyt

**Tested**

| | |
|---|---|
| **Species** | Human |

| | |
|---|---|
| **Dilution info** | - |
| **Notes** | - |

## Target data

See full target information CD22

| | |
|---|---|
| **Function** | Most highly expressed siglec (sialic acid-binding immunoglobulin-like lectin) on B-cells that plays a role in various aspects of B-cell biology including differentiation, antigen presentation, and trafficking to bone marrow (PubMed:34330755, PubMed:8627166). Binds to alpha 2,6-linked sialic acid residues of surface molecules such as CD22 itself, CD45 and IgM in a cis configuration. Can also bind to ligands on other cells as an adhesion molecule in a trans configuration (PubMed:20172905). Acts as an inhibitory coreceptor on the surface of B-cells and inhibits B-cell receptor induced signaling, characterized by inhibition of the calcium mobilization and cellular activation. Mechanistically, the immunoreceptor tyrosine-based inhibitory motif domain is phosphorylated by the Src kinase LYN, which in turn leads to the recruitment of the protein tyrosine phosphatase 1/PTPN6, leading to the negative regulation of BCR signaling (PubMed:8627166). If this negative signaling from is of sufficient strength, apoptosis of the B-cell can be induced (PubMed:20516366). |

## Storage

| | |
|---|---|
| **Shipped at conditions** | Blue Ice |
| **Appropriate short-term storage duration** | 1-2 weeks |
| **Appropriate short-term storage conditions** | +4°C |
| **Appropriate long-term storage conditions** | -20°C |
| **Aliquoting information** | Upon delivery aliquot |
| **Storage information** | Avoid freeze / thaw cycle |

## Supplementary info

This supplementary information is collated from multiple sources and compiled automatically.

| | |
|---|---|
| **Activity summary** | CD22 also known as Siglec-2 or B-lymphocyte cell adhesion molecule (BL-CAM) is a transmembrane protein with a mass of around 140 kDa. It is selectively expressed on the surface of mature B cells and some immature B cells. This protein plays an |

| | |
|---|---|
| | important role in the immune system particularly in the regulation of B cell function. CD22 functions by modulating signal transduction processes through its cytoplasmic domain which contains immunoreceptor tyrosine-based inhibitory motifs (ITIMs). |
| **Biological function summary** | CD22 acts mainly as a negative regulator of B cell receptor (BCR) signaling. It is part of a complex that interacts with the BCR and other accessory molecules. CD22 helps maintain B cell tolerance by inhibiting overactive signaling and preventing autoimmune responses. By binding to sialic acid-containing glycans CD22 modulates interactions between B cells and other cells aiding in the maintenance of immune homeostasis. |
| **Pathways** | CD22 plays a critical role in the BCR signaling pathway and the regulation of phosphatidylinositol 3-kinase (PI3K) signaling. It works together with proteins like CD19 and SHP-1 that are key components of these pathways. By influencing these signaling cascades CD22 contributes to the modulation of B cell activation proliferation and apoptosis ensuring proper functioning of the immune response. |
| **Associated diseases and disorders** | CD22 is associated with autoimmune conditions and hematological malignancies such as hairy cell leukemia (HCL). Therapeutic approaches targeting CD22 such as anti-CD22 antibodies are being explored for treating these diseases. CD22's role in these conditions is connected with proteins involved in the autoimmune pathways or cancer development offering potential therapeutic targets for intervention. |

## Product promise

**Tested**

We have tested this species and application combination and it works. It is covered by our product promise.

**Expected**

We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.

**Predicted**

This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.

**Not recommended**

We do not recommend this combination. It is not covered by our product promise.


---

We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.

In the unlikely event of one of our products not working as expected, you are covered by our product promise.

Full details and terms and conditions can be found here:
Terms & Conditions.

## 1 product image




### Flow Cytometry - Anti-CD22 antibody [MYG13] - BSA and Azide free (ab213038)

CD22 Flow Cytometry staining using mouse Anti-CD22 antibody

Flow Cytometry analysis of Ramos cells labeling CD22 with ab213038 followed by goat anti-Mouse IgG secondary (Blue); Isotype Control (Red).

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.